Bibliography
- Arrang JM, Garbarg M, Schwartz JC. Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 1985;15:553-62
- Chazot P, Fukui H, Ganellin CR, Histamine receptors: H3. IUPHAR database (IUPHAR-DB). Available from: http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=264. [Accessed on 18 October 2010]
- Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31(12):2163-81
- Lazewska D, Kiec-Kononowicz K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 2010;20(9):1147-69
- Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009;18(10):1519-31
- Taylor-Clark T, Sodha R, Warner B, Foreman J. Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005;144:867-74
- Norman P. A H3 antagonist for treating allergic rhinitis; a development candidate? Expert Opin Ther Pat 2007;17(4):449-52
- Beaton G, Moree WJ. The expanding role of H1 antihistamines: a patent survey of selective and dual activity compounds 2005-2010. Expert Opin Ther Pat 2010;20(9):1197-218
- Procopiou PA, Ancliff RA, Bamford MJ, 4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists. J Med Chem 2007;50(26):6706-17
- Glaxo Group Ltd. Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists. WO2004035556; 2004
- Glaxo Group Ltd. 2-Substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists. WO2007122156; 2007
- Ford A, Browning C, Russell L, K 145 Preclinical pharmacology of the novel oral dual histamine H1 and H3 receptor antagonist GSK835726 EAACI. Allergy 2009;64(S90):58
- Coe D, Fox D. Recent disclosures of clinical candidates; highlights of the society for medicines research symposium held December 10th 2009 at the National Heart And Lung Institute, London, UK. Drugs Future 2010;35(4):349-58
- Clark K, Russell L, Hall D, C 289 Preclinical pharmacology of the novel intranasal dual histamine H1 and H3 receptor antagonist GSK1004723. Allergy 2009;64(S90):129
- Slack R, Browning C, Hall D, GSK1004723, a novel histamine H1/H3 receptor antagonist exhibiting slow H1 dissociation kinetics. Br J Pharmacol 2009;158(S1):P142
- Available from: http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=112864&studyId=416F2C04-CC8B-4A1B-B20A-6BC159E8AE8C&compound=GSK1004723+and+GSK835726
- Available from: http://download.gsk-clinicalstudyregister.com/files/26388.pdf